Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06887907
Recruiting Observational

Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

NCT06887907 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Observational
Started
2025-03-13
Last updated
2025-03-20

Condition(s) studied

Sickle Cell Disease (SCD)

Study summary

Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Sickle cell disease SS or S-béta° thalassemia * Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome * Age \> 18 years old Exclusion Criteria: * Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome) * Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23 * Anti-platelets agents * Red blood cell exchange or transfusion \< 3 months

Primary outcome measure(s)

  • Description of circulant megakaryocytes — 12 months
    Phenotypic and transcriptomic description of circulant megakaryocytes in sickle cell patient

Trial sites (1)

FacilityCityRegionStatus
CHU de Toulouse Toulouse France Recruiting

More University Hospital, Toulouse trials in France

Intragastric Balloon in Obese Patients With Uncontrolled Asthma Recruiting
Study of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants Starting soon
Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement Starting soon
LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly Recruiting
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia Recruiting

Other trials for the same condition

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients Active, not recruiting
Exploratory Study on Global Reflexology in Sickle Cell Disease Recruiting
Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients Starting soon
Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation Starting soon
Epidemiology of Invasive Bacterial Infections in Children With Sickle Cell Disease in France Between 2020 and 2025 Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06887907 on ClinicalTrials.gov ↗ ← All trials in France